Some of what we learned at HCAA Executive Forum ’22

Some of what we learned at HCAA Executive Forum ’22

VativoRx sent a full team to HCAA Executive Forum ’22 in Las Vegas in February 2022. It was great to connect with friends new and old and to have our brains exploded a few times by the presenters.

On the last day in particular, two speakers – Marshall Allen and Galen Emanuele – stood out and left us with great ideas about how to approach the business of helping companies, their employees and their families to save on healthcare in general and prescription medicine in particular.

Marshall Allen is a journalist who has focused for years on teaching healthcare consumers to be aware of what they’re paying for their care and to equip them with the knowledge to fight back when appropriate.

At the HCAA Executive Forum, Allen spoke about how informed patients can avoid unnecessary care, stay away from high priced hospitals and other providers, and examine and contest medical bills for inaccuracies and overcharges. With each health care interaction, patients can save hundreds or even thousands of dollars if they are informed and on the alert. And when the patients save, their health plans save. Employers and employees can work together to lower health care costs.

To get a sense of how Marshall Allen approaches this topic, this recent interview is eye-opening. 

The very last event of the Forum was a keynote from former improv artist Galen Emanuele, who urges businesses to follow the one unbreakable rule of improv: Always try to say, “Yes. And…”

Resisting the urge to say “no” in business and to always try to say “yes” is central to Galen Emanuele’s advice to companies working to build successful and productive teams. Through hands-on learning, and tangible takeaways we experienced the impact that establishing a behavior-based culture has on team engagement, individual performance, and the ability to attract and retain top talent. By the end, there were few eye-rollers or non-believers left in the room.

Here’s a brief glimpse of what working with Galen is like:

Overall, HCAA Executive Forum ’22 was an outstanding gathering of people dedicated to making healthcare more accessible and affordable. We head home with our heads and notebooks full of excellent and actionable ideas.

VativoRx Joins MHA: A New Chapter Begins

The world of healthcare is dynamic, continuously evolving with new challenges and opportunities. At VativoRx, we’ve always believed in the power of innovation, collaboration, and dedication to ensure that we provide the best rebate management solutions in the industry. Today, we’re thrilled to announce our latest milestone: VativoRx is now an official associate member of the Michigan Health & Hospital Association (MHA)!

Read More »

Unveiling the Future: Navigating the Evolving Landscape of 340B Rebates.

The 340B Drug Pricing Program, established in 1992, has been a crucial component of the healthcare system, dedicated to assisting eligible healthcare organizations in serving vulnerable patient populations by granting them access to discounted drugs. At the heart of this program are the 340B rebates, which enable qualifying entities such as safety-net hospitals, community health centers, and other eligible providers to acquire medications at significantly reduced prices.

Read More »
Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »

Biosimilars — Similar But Not Identical

You may have never heard of biosimilar drugs and that’s probably because they are not commonly prescribed in the United States even though they have been around for over 20 years. So, what are biosimilar drugs? A biosimilar drug is no different in terms of safety and effectiveness than a biologic product, also known as a reference product, and while highly similar it is not identical.

Read More »

Lower Cost Prescription Drugs from Canada, Is It Legal?

In the early 2000s, the FDA set up guidelines in the Regulatory Procedures Manual (RPM) that permitted prescription drugs to be imported from other countries if the patient met very strict guidelines. Just stating that the patient needed the drug due to cost savings was not a justification to obtain the drug.

Read More »